PAK1 promotes intestinal tumor initiation

Cancer Prevention Research

Volumn 8, Issue 11, 2015, Pages 1093-1101

  Dammann, Kyle ^a   Khare, Vineeta ^a   Harpain, Felix ^a   Lang, Michaela ^a   Kurtovic, Azra ^a   Mesteri, Ildiko ^a   Evstatiev, Rayko ^a   Gasche, Christoph ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZOXYMETHANE; BETA CATENIN; CYCLIN D1; DEXTRAN SULFATE; MYC PROTEIN; P21 ACTIVATED KINASE 1; PROTEIN KINASE B; WNT PROTEIN; DEXTRAN; MESALAZINE; P21 ACTIVATED KINASE; PAK1 PROTEIN, MOUSE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARCHITECTURE; ARTICLE; CANCER MODEL; CHRONIC INFLAMMATION; COLITIS ASSOCIATED CANCER; COLONOSCOPY; CONTROLLED STUDY; DEXTRAN SODIUM SULFATE-INDUCED COLITIS; DYSPLASIA; EXPERIMENTAL CARCINOGENESIS; FEMALE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INTESTINE CANCER; INTESTINE CRYPT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR VOLUME; WILD TYPE; WNT SIGNALING PATHWAY; ANIMAL; C57BL MOUSE; CARCINOGENESIS; CHEMISTRY; GENE DELETION; GENE EXPRESSION REGULATION; GENOTYPE; HETEROZYGOTE; INFLAMMATION; INTESTINE TUMOR; KNOCKOUT MOUSE; METABOLISM;

ANIMALS; AZOXYMETHANE; BETA CATENIN; CARCINOGENESIS; COLONOSCOPY; DEXTRANS; FEMALE; GENE DELETION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOTYPE; HETEROZYGOTE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INTESTINAL NEOPLASMS; MALE; MESALAMINE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; P21-ACTIVATED KINASES; SIGNAL TRANSDUCTION;

EID: 84946111149     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-15-0205-T     Document Type: Article

References (42)

1. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology 2011;140:1807-16.
2. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol 2005;100:1345-53.
3. Rousseaux C, El-Jamal N, Fumery M, Dubuquoy C, Romano O, Chatelain D, et al. The 5-aminosalicylic acid antineoplastic effect in the intestine is mediated by PPARgamma. Carcinogenesis 2013;34:2580-6.
4. Lyakhovich A, Gasche C. Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine. Aliment Pharmacol Ther 2010;31:202-9.
5. Managlia E, Katzman RB, Brown JB, Barrett TA. Antioxidant properties of mesalamine in colitis inhibit phosphoinositide 3-kinase signaling in progenitor cells. Inflamm Bowel Dis 2013;19:2051-60.
6. Luciani MG, Campregher C, Fortune JM, Kunkel TA, Gasche C. 5-ASA affects cell cycle progression in colorectal cells by reversibly activating a replication checkpoint. Gastroenterology 2007;132:221-35.
7. Brown JB, Lee G, Managlia E, Grimm GR, Dirisina R, Goretsky T, et al. Mesalamine inhibits epithelial beta-catenin activation in chronic ulcerative colitis. Gastroenterology 2010;138:595-605, e1-3.
8. Kim H, Jeon H, Kong H, Yang Y, Choi B, Kim YM, et al. A molecular mechanism for the anti-inflammatory effect of taurine-conjugated 5-aminosalicylic acid in inflamed colon. Mol Pharmacol 2006;69:1405-12.
9. Khare V, Lang M, Dammann K, Campregher C, Lyakhovich A, Gasche C. Modulation of N-glycosylation by mesalamine facilitates membranous Ecadherin expression in colon epithelial cells. Biochem Pharmacol 2014;87:312-20.
10. Khare V, Lyakhovich A, Dammann K, Lang M, Borgmann M, Tichy B, et al. Mesalamine modulates intercellular adhesion through inhibition of p-21 activated kinase-1. Biochem Pharmacol 2013;85:234-44.
11. Eswaran J, Li DQ, Shah A, Kumar R. Molecular pathways: targeting p21-activated kinase 1 signaling in cancer-opportunities, challenges, and limitations. Clin Cancer Res 2012;18:3743-9.
12. Dammann K, Khare V, Gasche C. Tracing PAKs from GI inflammation to cancer. Gut 2014;63:1173-84.
13. Zhu G, Wang Y, Huang B, Liang J, Ding Y, Xu A, et al. A Rac1/PAK1 cascade controls beta-catenin activation in colon cancer cells. Oncogene 2012;31:1001-12.
14. Park MH, Kim DJ, You ST, Lee CS, Kim HK, Park SM, et al. Phosphorylation of beta-catenin at serine 663 regulates its transcriptional activity. Biochem Biophys Res Commun 2012;419:543-9.
15. Frost JA, Swantek JL, Stippec S, Yin MJ, Gaynor R, Cobb MH. Stimulation of NFkappa B activity by multiple signaling pathways requires PAK1. J Biol Chem 2000;275:19693-9.
16. Selyunin AS, Alto NM. Activation of PAK by a bacterial type III effector EspG reveals alternative mechanisms of GTPase pathway regulation. Small GTPases 2011;2:217-21.
17. Dammann K, Khare V, Lang M, Claudel T, Harpain F, Granofszky N, et al. PAK1 modulates a PPARgamma/NF-kappaB cascade in intestinal inflammation. Biochim Biophys Acta 2015;1853:2349-60.
18. Khare V, Dammann K, Asboth M, Krnjic A, Jambrich M, Gasche C. Overexpression of PAK1 promotes cell survival in inflammatory bowel diseases and colitis-associated cancer. Inflamm Bowel Dis 2015;21:287-96.
19. Carter JH, Douglass LE, Deddens JA, Colligan BM, Bhatt TR, Pemberton JO, et al. Pak-1 expression increases with progression of colorectal carcinomas to metastasis. Clin Cancer Res 2004;10:3448-56.
20. He H, Huynh N, Liu KH, Malcontenti-Wilson C, Zhu J, Christophi C, et al. P-21 activated kinase 1 knockdown inhibits beta-catenin signalling and blocks colorectal cancer growth. Cancer Lett 2012;317:65-71.
21. Lang M, Borgmann M, Oberhuber G, Evstatiev R, Jimenez K, Dammann KW, et al. Thymoquinone attenuates tumor growth in ApcMin mice by interference with Wnt-signaling. Mol Cancer 2013;12:41.
22. McDaniel AS, Allen JD, Park SJ, Jaffer ZM, Michels EG, Burgin SJ, et al. Pak1 regulates multiple c-Kit mediated Ras-MAPK gain-in-function phenotypes in Nf1+/-mast cells. Blood 2008;112:4646-54.
23. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 1993;69:238-49.
24. Suzuki R, Kohno H, Sugie S, Nakagama H, Tanaka T. Strain differences in the susceptibility to azoxymethane and dextran sodium sulfate-induced colon carcinogenesis in mice. Carcinogenesis 2006;27:162-9.
25. Barker N, Ridgway RA, Van Es JH, Van De Wetering M, Begthel H, Van Den Born M, et al. Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 2009;457:608-11.
26. Higuchi M, Onishi K, Kikuchi C, Gotoh Y. Scaffolding function of PAK in the PDK1-Akt pathway. Nat Cell Biol 2008;10:1356-64.
27. Campregher C, Gasche C. Aminosalicylates. Best Pract Res Clin Gastroenterol 2011;25:535-46.
28. Baan B, Dihal AA, Hoff E, Bos CL, Voorneveld PW, Koelink PJ, et al. 5-Aminosalicylic acid inhibits cell cycle progression in a phospholipase D dependent manner in colorectal cancer. Gut 2012;61:1708-15.
29. Rubin DT, Cruz-Correa MR, Gasche C, Jass JR, Lichtenstein GR, Montgomery EA, et al. Colorectal cancer prevention in inflammatory bowel disease and the role of 5-aminosalicylic acid: a clinical review and update. Inflamm Bowel Dis 2008;14:265-74.
30. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature 2008;454:436-44.
31. Najdi R, Holcombe RF, Waterman ML. Wnt signaling and colon carcinogenesis: beyond APC. J Carcinog 2011;10:5.
32. Schepers A, Clevers H. Wnt signaling, stem cells, and cancer of the gastrointestinal tract. Cold Spring Harbor Perspect Biol 2012;4:a007989.
33. Su LK, Kinzler KW, Vogelstein B, Preisinger AC, Moser AR, Luongo C, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 1992;256:668-70.
34. Ignatenko NA, Holubec H, Besselsen DG, Blohm-Mangone KA, Padilla-Torres JL, Nagle RB, et al. Role of c-Myc in intestinal tumorigenesis of the ApcMin/+ mouse. Cancer Biol Ther 2006;5:1658-64.
35. Mazumdar A, Kumar R. Estrogen regulation of Pak1 and FKHR pathways in breast cancer cells. FEBS Lett 2003;535:6-10.
36. Gu S, Kounenidakis M, Schmidt EM, Deshpande D, Alkahtani S, Alarifi S, et al. Rapid activation of FAK/mTOR/p70S6K/PAK1-signaling controls the early testosterone-induced actin reorganization in colon cancer cells. Cell Signal 2013;25:66-73.
37. Rousseaux C, Lefebvre B, Dubuquoy L, Lefebvre P, Romano O, Auwerx J, et al. Intestinal antiinflammatory effect of 5-aminosalicylic acid is dependent on peroxisome proliferator-activated receptor-gamma. J Exp Med 2005;201:1205-15.
38. Li Y, Shao Y, Tong Y, Shen T, Zhang J, Li Y, et al. Nucleo-cytoplasmic shuttling of PAK4 modulates beta-catenin intracellular translocation and signaling. Biochim Biophys Acta 2012;1823:465-75.
39. Pham H, Vincenti R, Slice LW. COX-2 promoter activation by AT1R-Gq-PAK-p38beta signaling in intestinal epithelial cells. Biochim Biophys Acta 2008;1779:408-13.
40. Wu R, Abramson AL, Symons MH, Steinberg BM. Pak1 and Pak2 are activated in recurrent respiratory papillomas, contributing to one pathway of Rac1-mediated COX-2 expression. Int J Cancer 2010;127:2230-7.
41. Paccani SR, Patrussi L, Ulivieri C, Masferrer JL, D'Elios MM, Baldari CT. Nonsteroidal anti-inflammatory drugs inhibit a Fyn-dependent pathway coupled to Rac and stress kinase activation in TCR signaling. Blood 2005;105:2042-8.
42. Allen JD, Jaffer ZM, Park SJ, Burgin S, Hofmann C, Sells MA, et al. p21-activated kinase regulates mast cell degranulation via effects on calcium mobilization and cytoskeletal dynamics. Blood 2009;113:2695-705.